Uso da metformina como agente emagrecedor

A obesidade tem atingido altos índices em toda a população, conjuntamente às Doenças Crônicas não Transmissíveis, em destaque o Diabetes Tipo II e a resistência à insulina. A metformina é um fármaco de uso para o tratamento do Diabetes Tipo II e pré-diabetes em pacientes obesos. O objetivo destes estudos é comparar resultados do uso da metformina em pacientes obesos não diabéticos, com IMC elevado e avaliar se houve melhora nos parâmetros antropométricos e também no perfil metabólico. Dentre os estudos avaliados o IMC foi reduzido juntamente com o peso demonstrando que há eficácia da metformina, mas não efetividade, pois os valores obtidos não foram suficientes para o indivíduo deixar de ser obeso. Contudo, observou-se melhora no perfil metabólico geral da população o que coloca a metformina numa posição de fármaco para tratamento do pré-diabetes e doenças correlacionadas com a obesidade. ABSTRACT Use of metformin as a slimming agentObesity has reached high levels in the population and together comes the Chronic Diseases Noncommunicable, the Type II Diabetes and insulin resistance. Metformin is a drug used for treat type II diabetes and pre-diabetes in obese patients. The objective of these studies is to compare results of the use of metformin in non-diabetic obese patients with high BMI and assess whether there was an improvement in anthropometric parameters and also in the metabolic profile. Among the studies assessed, BMI was reduced along with weight, demonstrating that there is efficacy of metformin, but it isn't effective, because the values were not enough for the individual stop being obese. However, there was a general improvement in the metabolic profile of the population that places the drug Metformin in a position for pre - treating diabetes and diseases correlated with obesity

Uso da metformina como agente emagrecedor

A obesidade tem atingido altos índices em toda a população, conjuntamente às Doenças Crônicas não Transmissíveis, em destaque o Diabetes Tipo II e a resistência à insulina. A metformina é um fármaco de uso para o tratamento do Diabetes Tipo II e pré-diabetes em pacientes obesos. O objetivo destes estudos é comparar resultados do uso da metformina em pacientes obesos não diabéticos, com IMC elevado e avaliar se houve melhora nos parâmetros antropométricos e também no perfil metabólico. Dentre os estudos avaliados o IMC foi reduzido juntamente com o peso demonstrando que há eficácia da metformina, mas não efetividade, pois os valores obtidos não foram suficientes para o indivíduo deixar de ser obeso. Contudo, observou-se melhora no perfil metabólico geral da população o que coloca a metformina numa posição de fármaco para tratamento do pré-diabetes e doenças correlacionadas com a obesidade. ABSTRACT Use of metformin as a slimming agentObesity has reached high levels in the population and together comes the Chronic Diseases Noncommunicable, the Type II Diabetes and insulin resistance. Metformin is a drug used for treat type II diabetes and pre-diabetes in obese patients. The objective of these studies is to compare results of the use of metformin in non-diabetic obese patients with high BMI and assess whether there was an improvement in anthropometric parameters and also in the metabolic profile. Among the studies assessed, BMI was reduced along with weight, demonstrating that there is efficacy of metformin, but it isn't effective, because the values were not enough for the individual stop being obese. However, there was a general improvement in the metabolic profile of the population that places the drug Metformin in a position for pre - treating diabetes and diseases correlated with obesity

Identification of proteins from a cell wall fraction of the diatom Thalassiosira pseudonana : insights into silica structure formation

Diatoms are unicellular eucaryotic algae with cell walls containing silica, intricately and ornately structured on the nanometer scale. Overall silica structure is formed by expansion and molding of the membrane-bound silica deposition vesicle. Although molecular details of silica polymerization are being clarified, we have limited insight into molecular components of the silica deposition vesicle, particularly of membrane-associated proteins that may be involved in structure formation. To identify such proteins, we refined existing procedures to isolate an enriched cell wall fraction from the diatom Thalassiosira pseudonana, the first diatom with a sequenced genome. We applied tandem mass spectrometric analysis to this fraction, identifying 31 proteins for further evaluation. mRNA levels for genes encoding these proteins were monitored during synchronized progression through the cell cycle and compared with two previously identified silaffin genes (involved in silica polymerization) having distinct mRNA patterns that served as markers for cell wall formation. Of the 31 proteins identified, 10 had mRNA patterns that correlated with the silaffins, 13 had patterns that did not, and seven had patterns that correlated but also showed additional features. The possible involvements of these proteins in cell wall synthesis are discussed. In particular, glutamate acetyltransferase was identified, prompting an analysis of mRNA patterns for other genes in the polyamine biosynthesis pathway and identification of those induced during cell wall synthesis. Application of a specific enzymatic inhibitor for ornithine decarboxylase resulted in dramatic alteration of silica structure, confirming the involvement of polyamines and demonstrating that manipulation of proteins involved in cell wall synthesis can alter structure. To our knowledge, this is the first proteomic analysis of a diatom, and furthermore we identified new candidate genes involved in structure formation and directly demonstrated the involvement of one enzyme (and its gene) in the structure formation process.12 page(s

LOCALIZATION OF THE BREAKPOINT IN THE M-BCR IN 31 CASES OF CML. PRELIMINARY OBSERVATIONS.

HAEMATOLOGICA , SUPPLEMENTO NO